

## IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/US03/11497

International Filing Date : 15 April 2003 (15.04.2003)

U.S. Serial No. : 10/511,538

Deposit Date U.S. Nat'l Phase : October 18, 2004

Priority Date(s) Claimed : 16 April 2002 (16.04.2002)

Applicant(s) : Gilbert JAY, et al.

Title: TISSUE SPECIFIC GENES AND GENE CLUSTERS

## **INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

## Timing and Fees

Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:		
	within three months of the filing date of a national application other than a CPA under § 1.53(d);	
$\boxtimes$	within three months of the actual filing date of the national phase of a PCT application; OR	
	before the mailing of a first substantive office action (including after filing of an RCE).	
Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after specified in 37 C.F.R. § 1.97(b), but before the mailing date of:		
	a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and	
	disclos	

		is accompanied by:				
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR			
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).			
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:			
		a final	action under 37 C.F.R. § 1.113;			
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);			
		OR a r	notice of allowance under 37 C.F.R. § 1.311;			
	AND i	s filed o	on or before payment of the issue fee; AND is accompanied by:			
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 0 under 37 C.F.R. § 1.17(p).			
Staten	nents Ur	nder 37	C.F.R. 1.97(e)			
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or			
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.			
Cited	Materia	<u>ls</u>				
		ancest	of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).			
	$\boxtimes$	-	s of materials listed but not attached were cited in an international search dated May 12, 2005.			
		Not re	quired by 37 CFR § 1.98.			
		Copies	s of the materials listed are attached (except for the foregoing).			
			^			

An English-language search report or equivalent paper from a foreign pater office is provided indicating the relevance of the cited reference(s).	nt
A foreign-language search report from a foreign patent office is provided, ar pertinent parts are translated substantively below:	nd
<ul> <li>X = document of particular relevance when it is taken alone</li> <li>Y = document of particular relevance when it is combined with another sucdocument</li> </ul>	ch
A = document defining the general state of the art	
O = non-written disclosure P = intercalated document	
T = document cited to understand the theory or principle underlying the invention	he
E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date	ate
D = cited in the application	
L = cited for another reason	
& = publication of member of same patent family	
Translation of other relevant information on foreign search report	
Other Information	
Payment of Fees Due (If Any):	
A check for \$ covering the fee identified above is attached.	

Please charge to Deposit Account No. 13-3402 \$\_\_\_\_\_ for the fee identified above.



The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Richard M. Lebovitz, Reg. No.: 37,067

Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza l
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333

Facsimile: (703) 243-6333

Attorney Docket No.: ORIGEN-0036

Date: August 18, 2005

RML/ssr



Please type a plus sign (+) inside this box -> +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known		
				Application Number	USNP of PCT/US03/11497	
INFO	RMATION	DISC	LOSURE	Filing Date	15 April 2003 (15.04.2003)	
STATEMENT BY APPLICANT  (use as many sheets as necessary)				First Named Inventor	Gilbert JAY, et al.	
				Group Art Unit	unknown	
				Examiner Name	unknown	
Sheet	1	of	1	Attorney Docket Number	ORIGEN-0036	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>		
	001	KONO, D.H. et al.: RESISTANCE TO EXNOBIOTIC-INDUCED AUTOMMUNITY MAPS TO CHROMOSOME 1. THE JOURNAL OF IMMUNOLOGY, 2001. vol 167, pages 2396-2403			
			-		

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.